Cited by 452BRCA gene mutations in cancerBreast Lesions and CarcinomasBreast Cancer Treatment Studies

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Verhoog, LC, Brekelmans, CTM, Seynaeve, C, van den Bosch, LMC, Dahmen, G, van Geel, AN, Tilanus-Linthorst, MMA, Bartels, CCM, Wagner, A, van den Ouweland, A, Devilee, P, Meijers-Heijboer, EJ, Klijn, JGM·1998·The Lancet

DOI 10.1016/s0140-6736(97)07065-7

Open this paper in CoChat — free account

Abstract

Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration.Methods We estimated disease-free and overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis.Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(97)07065-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,391
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Age as prognostic factor in premenopausal breast carcinoma
de la Rochefordière, A., Campana, F., Fenton, J., Vilcoq, J. R., Fourquet, A., Asselain, B. J. R., Scholl, S. M., Pouillart, P., Durand, J., & Magdelénat, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)92407-k · Cited by 481
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citation
Tumour biological features of BRCA1-induced breast and ovarian cancer
Johannsson, O. T., Idvall, I., Anderson, C., Borg, Å., Barkardottir, R. B., Egilsson, V., & Olsson, H. L. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 344

Show all 31 references

Research works printed but not linked: 3

Lynch, 1993, Increased proliferation in hereditary breast cancer, Proc ASCO, 12, 82
Lynch, 1994, Distinctive clinicopathological features of BRCA1 linked hereditary breast cancer, Proc ASCO, 13, 56
Solin, 1996, Breast cancer in young women: the University of Pennsylvania experience—breast cancer: advances in biology and therapeutics, John Libbey Eurotext, 351

Sorted by citations

Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,451
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I. A., Duggan, D. J., Chen, Y., Radmacher, M. D., Bittner, M. L., Simon, R., Meltzer, P. S., Gusterson, B. A., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,732
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Self-citation
Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2
King, M. (2001) · JAMA · doi:10.1001/jama.286.18.2251 · Cited by 776
Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer
Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R. T., Freedman, L. S., Helzlsouer, K. J., & Vogel, V. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1829 · Cited by 662
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S. S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
Lakhani, S. R., Reis-Filho, J. S., Fulford, L. G., Penault-Llorca, F. M., van de Vijver, M. J., Parry, S., Bishop, D. T., Benitez, J. J., Rivas, C., Bignon, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
Self-citation
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
Anglian Breast Cancer Study Group (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 602
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod, S., Brunet, J., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., Ríos, P. D. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 557
Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results.
Kuhl, C. K., Schmutzler, R., Leutner, C., Kempe, A., Wardelmann, E., Hocke, A., Maringa, M., Pfeifer, U., Krebs, D., & Schild, H. (2000) · Radiology · doi:10.1148/radiology.215.1.r00ap01267 · Cited by 584
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Copson, E., Maishman, T., Tapper, W., Cutress, R., Greville-Heygate, S. L., Altman, D. G., Eccles, B., Gerty, S. M., Durcan, L., Jones, J. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30891-4 · Cited by 483
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1260 · Cited by 404
Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study
Burn, J., Brennan, P., Little, J., Holloway, S., Coffey, R., Somerville, J., Dennis, N., Allan, L. D., Arnold, R., Deanfield, J. E., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06486-6 · Cited by 397
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Warner, E., Foulkes, W., Goodwin, P., Meschino, W., Blondal, J., Paterson, C., Ozçelik, H., Goss, P., Allingham-Hawkins, D., Hamel, N., et al. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.14.1241 · Cited by 421
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
Hall, M., Reid, J., Burbidge, L. A., Pruss, D., Deffenbaugh, A. M., Frye, C., Wenstrup, R., Ward, B. E., Scholl, T., & Noll, W. (2009) · Cancer · doi:10.1002/cncr.24200 · Cited by 360
Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 351
Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results
Sardanelli, F., Podo, F., D'Agnolo, G., Verdecchia, A., Santaquilani, M., Musumeci, R., Trecate, G., Manoukian, S., Morassut, S., de Giacomi, C., et al. (2007) · Radiology · doi:10.1148/radiol.2423051965 · Cited by 339
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer, E. J., Verhoog, L., Brekelmans, C., Seynaeve, C., Tilanus-Linthorst, M., Wagner, A., Dukel, L., Devilee, P., van den Ouweland, A. V. D., van Geel, A. V., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02347-3 · Cited by 328
Self-citation
Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk
Brekelmans, C. T. M., Seynaeve, C., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., Meijers-Heijboer, E. J., Crépin, C., van Geel, A. N., Menke, M., Verhoog, L. C., van den Ouweland, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.924 · Cited by 306
Self-citation
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, F., Buydens, L. M. C., Degani, H., Hilhorst, R., Klipp, E., Gribbestad, I. S., Van Huffel, S., W.M. van Laarhoven, H., Luts, J., Monleon, D., et al. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.006 · Cited by 299
The genetics of breast cancer susceptibility.
Rahman, N., & Stratton, M. R. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.95 · Cited by 324
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
van Sprundel, T. C., Schmidt, M. K., Rookus, M. A., Brohet, R. M., van Asperen, C. J., Rutgers, E. J. T., Veer, L. J. V., & Tollenaar, R. A. �. �. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602703 · Cited by 291
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
Pierce, L., Strawderman, M., Narod, S., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L., Nixon, A., Garber, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3360 · Cited by 270
Efficacy of Contralateral Prophylactic Mastectomy in Women With a Personal and Family History of Breast Cancer
McDonnell, S. K., Schaid, D. J., Myers, J. L., Grant, C. S., Donohue, J. H., Woods, J. E., Frost, M. H., Johnson, J. L., Sitta, D. L., Slezak, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3938 · Cited by 264
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B., Kim‐Sing, C., Olsson, H. L., Ainsworth, P., Eisen, A. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 253
Advanced Approaches to Breast Cancer Classification and Diagnosis
Zubair, M., Wang, S., & Ali, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.632079 · Cited by 285
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
Wessels, L. F. A., van Welsem, T., Hart, A. A. M., Veer, L. J. V., Reinders, M. J. T., & Nederlof, P. M. (2002) · PubMed · Cited by 252
Multi-class cancer classification via partial least squares with gene expression profiles
Nguyen, D. V., & Rocke, D. M. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.9.1216 · Cited by 246
Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode, E. L., Dunning, A. M., Kuschel, B., Healey, C. S., Day, N., Ponder, B. A. J., Easton, D. F., & Pharoah, P. D. P. (2002) · PubMed · Cited by 239
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L., Kauff, N. D., Robson, M. E., Kelly, B. N., Barakat, R. R., Satagopan, J. M., Ellis, N. A., Hensley, M. L., Boyd, J. A., Borgen, P. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1260 · Cited by 239
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
Background
Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., Cai, H., & Zou, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1465 · Cited by 234
Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag, D., Kuntz, K., Garber, J., & Weeks, J. (2000) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.283.5.617 · Cited by 235
Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis
Heemskerk‐Gerritsen, B. A. M., Rookus, M. A., Aalfs, C. M., Ausems, M. G. E. M., Collée, J. M., Jansen, L., Kets, C. M., Keymeulen, K., Koppert, L. B., Meijers-Heijboer, H. E. J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29032 · Cited by 221
Self-citation
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy
Pierce, L. J., Phillips, K., Griffith, K. A., Buys, S. S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M. A., Kaufman, B., Garber, J. E., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0894-z · Cited by 200
Satisfaction After Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance
Frost, M. H., Slezak, J. M., Tran, N. V., Williams, C. I., Johnson, J. L., Woods, J. E., Petty, P. M., Donohue, J. H., Grant, C. S., Sloan, J. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.233 · Cited by 197
Molecular Basis for Estrogen Receptor Deficiency in BRCA1-Linked Breast Cancer
Hosey, A. M., Gorski, J. J., Murray, M. M., Quinn, J. E., Chung, W. Y., Stewart, G. E., James, C., Farragher, S., Mulligan, J. M., Scott, A. N., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm207 · Cited by 197
Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2
Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., Xue, S., Teraoka, S., Bernstein, L., Capanu, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2495 · Cited by 191
Issues of Regret in Women With Contralateral Prophylactic Mastectomies
Montgomery, L., Tran, K. N., Heelan, M. C., Zee, K. V., Massie, M., Payne, D., & Borgen, P. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0542-1 · Cited by 194
BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus‐Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2294 · Cited by 183
Self-citation
Pathology of hereditary breast cancer
van der Groep, P., van der Wall, E., & van Diest, P. J. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0010-3 · Cited by 190
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe, K., Lubiński, J., Ghadirian, P., Lynch, H., Kim-sing, C., Friedman, E., Foulkes, W., Domchek, S., Ainsworth, P., Isaacs, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6078 · Cited by 197
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., Clough, K., Magdelénat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4053 · Cited by 224
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog, L., Brekelmans, C., Seynaeve, C., Dahmen, G., van Geel, A. V., Bartels, C., Tilanus-Linthorst, M., Wagner, A., Devilee, P., Halley, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3396 · Cited by 197
Self-citation
Breast cancer genetics in African Americans
Olopade, O. I., Fackenthal, J. D., Dunston, G. M., Tainsky, M. A., Collins, F. S., & Whitfield-Broome, C. (2002) · Cancer · doi:10.1002/cncr.11019 · Cited by 175
BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays
Bane, A., Beck, J., Bleiweiss, I., Buys, S., Catalano, E., Daly, M., Giles, G., Godwin, A., Hibshoosh, H., Hopper, J., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213351.49767.0f · Cited by 181
Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study
Goodwin, P. J., Phillips, K., West, D. W., Ennis, M., Hopper, J. L., John, E. M., O’Malley, F. P., Milne, R. L., Andrulis, I. L., Friedlander, M. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0068 · Cited by 167
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
Robson, M., Levin, D., Federici, M. G., Satagopan, J. M., Bogolminy, F., Heerdt, A., Borgen, P., Mccormick, B., Hudis, C., Norton, L., et al. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2112 · Cited by 181
Genes implicated in hereditary breast cancer syndromes.
Tonin, P. (2000) · Seminars in surgical oncology · doi:10.1002/(sici)1098-2388(200006)18:4 · Cited by 35
Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9449-x · Cited by 153
“of women (N) 145 (82) 32 (18) 91 (50) 90 (50) <.”
Self-citation
Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation
Anderson, K. N., Jacobson, J. S., Heitjan, D. F., Zivin, J. G., Hershman, D. L., Neugut, A. I., & Grann, V. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00006 · Cited by 151
Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer: An Increasing Trend at a Single Institution
Jones, N., Wilson, J. L., Kotur, L., Stephens, J. A., Farrar, W. B., & Agnese, D. M. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0547-9 · Cited by 150
Effect of Prevention Strategies on Survival and Quality-Adjusted Survival of Women With BRCA1/2 Mutations: An Updated Decision Analysis
Grann, V. R., Jacobson, J. S., Thomason, D., Hershman, D. L., Heitjan, D. F., & Neugut, A. I. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.101 · Cited by 149
Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing.
Simon, M., & Petrucelli, N. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-416-2_25 · Cited by 132
Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy
Yi, M., Hunt, K. K., Arun, B., Bedrosian, I., Gutierrez‐Barrera, A. M., Do, K.-A., Kuerer, H. M., Babiera, G. V., Mittendorf, E. A., Ready, K. J., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0130 · Cited by 143
Alcohol and Postmenopausal Breast Cancer Risk Defined by Estrogen and Progesterone Receptor Status: A Prospective Cohort Study
Suzuki, R., Ye, W., Rylander‐Rudqvist, T., Saji, S., Colditz, G. A., & Wolk, A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji341 · Cited by 136
Survival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 136
Self-citation
Prognosis of BRCA-associated breast cancer: a summary of evidence
Bordeleau, L., Panchal, S., & Goodwin, P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0566-z · Cited by 135
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Lim, J. Y., Yang, K. Y., Taylor‐Harding, B., Wiedemeyer, W. R., & Buckanovich, R. J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.003 · Cited by 131
Hereditary breast cancer
Robson, M. E., Boyd, J. A., Borgen, P. I., & Cody, H. S. (2001) · Current Problems in Surgery · doi:10.1016/s0011-3840(01)70035-4 · Cited by 133
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
Verhoog, L., Brekelmans, C., Seynaeve, C., Meijers-Heijboer, E., & Klijn, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1239 · Cited by 135
Self-citation
Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2
Robson, M. E., Svahn, T. H., McCormick, B. L., Borgen, P. I., Hudis, C. A., Norton, L., & Offit, K. (2004) · Cancer · doi:10.1002/cncr.20728 · Cited by 126
Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis
van den Broek, A. J., Schmidt, M. K., Veer, L. V. ‘., Tollenaar, R. A. �. �., & van Leeuwen, F. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120189 · Cited by 133
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer, H., Brekelmans, C., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., Crepin, E., van den Ouweland, A. V. D., van Geel, B. V., & Klijn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.052 · Cited by 150
Self-citation
Contralateral Prophylactic Mastectomy After Unilateral Breast Cancer
Fayanju, O. M., Stoll, C. R. T., Fowler, S. A., Colditz, G. A., & Margenthaler, J. A. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000769 · Cited by 118
Recognition and Management of Hereditary Breast Cancer Syndromes
Thull, D. L., & Vogel, V. G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-13 · Cited by 118
BRCA1 : mechanisms of inactivation and implications for management of patients
Kennedy, R. D., Quinn, J. E., Johnston, P. G., & Harkin, D. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11087-7 · Cited by 116
Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?
Sardanelli, F., & Podo, F. (2006) · European Radiology · doi:10.1007/s00330-006-0389-9 · Cited by 116
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant
de Bock, G. H., Schutte, M., Krol-Warmerdam, E. M. M., Seynaeve, C., Blom, J., Brekelmans, C. T. M., Meijers-Heijboer, H. E. J., van Asperen, C. J., Cornelisse, C. J., Devilee, P., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.019737 · Cited by 114
Self-citation
Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Møller, P., Borg, Å., Evans, D. G., Kingsbury, N., Reis, M. M., Vasen, H. F. A., Anderson, E. D. C., Steel, C. M., Apold, J., Goudie, D. R., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10641 · Cited by 113
Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas
Takagi, S., Kinouchi, Y., Hiwatashi, N., Chida, M., Nagashima, F., Takahashi, S., Negoro, K., Shimosegawa, T., & Toyota, T. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8 · Cited by 47
Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ
Claus, E. B. (2005) · JAMA · doi:10.1001/jama.293.8.964 · Cited by 111
BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
Turner, B. C., Harrold, E., Matloff, E., Smith, T., GUMBS, A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P., Thomas, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3017 · Cited by 118
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
Self-citation
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., Blom, J., Huijskens, E., Jager, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9067 · Cited by 104
Self-citation
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Lee, J. S., Wacholder, S., Struewing, J., McAdams, M., Pee, D., Brody, L., Tucker, M. A., & Hartge, P. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.3.259 · Cited by 113
The role of BRCA mutation testing in determining breast cancer therapy
Trainer, A. H., Lewis, C. R., Tucker, K., Meiser, B., Friedlander, M. L., & Ward, R. L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.175 · Cited by 100
Effects of calcium channel blockers on cellular apoptosis
Mason, R. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990515)85:10 · Cited by 47
Molecular assays for surveillance of antifolate-resistant malaria
Kublin, J. G., WITZIG, R. S., Shankar, A. H., Zurita, J. Q., Gilman, R. H., Guarda, J. A., Cortese, J. F., & Plowe, C. V. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24022-0 · Cited by 97
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
Møller, P., Evans, D. G., Reis, M. M., Gregory, H., Anderson, E. D. C., Mæhle, L., Lalloo, F. I., Howell, A., Apold, J., Clark, N., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22789 · Cited by 95
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
Tung, N., Wang, Y., Collins, L. C., Kaplan, J., Li, H., Gelman, R. S., Comander, A. H., Gallagher, B. M., Fetten, K., Krag, K. J., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2478 · Cited by 94
Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
Phillips, K., Andrulis, I., & Goodwin, P. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3653 · Cited by 103
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
Seynaeve, C., Verhoog, L. C., van de Bosch, L. M. C., van Geel, A. N., Menke-Pluymers, M., Meijers-Heijboer, E. J., van den Ouweland, A. M. W., Wagner, A., Creutzberg, C. L., Niermeijer, M. F., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.017 · Cited by 93
Self-citation
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature
Calderon‐Margalit, R., & Paltiel, O. (2004) · International Journal of Cancer · doi:10.1002/ijc.20429 · Cited by 92
Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy
van Roosmalen, M. S., Verhoef, L. C. G., Stalmeier, P. F. M., Hoogerbrugge, N., & van Daal, W. A. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.035 · Cited by 91
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study
Broeks, A., Braaf, L. M., Huseinovic, A., Nooijen, A., Urbanus, J. H. M., Hogervorst, F. B. L., Schmidt, M. K., Klijn, J. G. M., Russell, N. S., van Leeuwen, F. E., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1668 · Cited by 89
Self-citation
Advances in Breast Conservation Therapy
Newman, L. A., & Kuerer, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.046 · Cited by 88
Breast cancer prevention: a review of current evidence
Vogel, V. G. (2000) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.3.156 · Cited by 87
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis
Zhu, Y., Wu, J., Zhang, C., Sun, S., Zhang, J., Liu, W., Huang, J., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12158 · Cited by 92
BRCA1 in hormonal carcinogenesis: basic and clinical research
Rosen, E. M., Fan, S., & Isaacs, C. J. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00972 · Cited by 86

Authors: Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., Devilee, P., Meijers-Heijboer, E., & Klijn, J.
Affiliations: Academisch Ziekenhuis Rotterdam (NL)
Erasmus University Rotterdam (NL)
Leiden University (NL)
Corresponding author: Klijn, JGM
ORCID: Wagner, A
Devilee, P
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-01
Volume: 351
Issue: 9099
Pages: 316-321
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(97)07065-7
OpenAlex: W2137086763
Cited by: 452
References: 31
Citations by year: 2026: 3 · 2025: 8 · 2024: 3 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 13 · 2014: 10 · 2013: 7 · 2012: 5
FWCI: 28.46
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: KWF Kankerbestrijding
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: hereditary breast cancer, BRCA1 mutation, sporadic breast cancer, disease-free survival, overall survival, contralateral breast cancer, estrogen receptor status, tumor characteristics, tumor recurrence, breast cancer screening
MeSH terms: Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Prognosis, Risk, Odds Ratio, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks